by Plexium | Jan 16, 2024 | All Posts, Press Releases
San Diego, California, January 16, 2024 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of...
by Plexium | Dec 12, 2023 | All Posts, Press Releases
San Diego, California, December 12, 2023 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation company, today reported that the first subjects have been dosed in a Phase 1 clinical study of orally administered PLX-4545, a potent and...
by Plexium | Sep 29, 2022 | All Posts, Press Releases
San Diego, California, September 29, 2022 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Suzanne Zoumaras as Executive Vice President, Head of Human Resources. Ms. Zoumaras is an...
by Amy Conrad | Aug 24, 2022 | All Posts
San Diego, California, [August 24, 2022] – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Daniel Sipes as Senior Vice President, Head of Technology. Mr. Sipes brings over two decades of...
by Plexium | Nov 4, 2021 | All Posts, Press Releases
San Diego, Calif., November 4, 2021 – Plexium Inc., (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer...
by Plexium | Oct 7, 2021 | All Posts, Press Releases
SAN DIEGO, Oct. 5, 2021 – Plexium Inc., (Plexium), a biotech company focused on discovering and developing protein degrading therapeutics directed towards historically challenging drug targets, today announced that company management will present and host one-on-one...